Mucinous Colorectal Cancer and Chemotherapy Response
Author Information
Author(s): Glasgow S C, Yu J, Carvalho L P, Shannon W D, Fleshman J W, McLeod H L
Primary Institution: Washington University School of Medicine
Hypothesis
Mucinous colorectal cancer may have a differential response to adjuvant chemotherapy compared to nonmucinous colorectal cancer due to the expression of certain molecular markers.
Conclusion
Mucinous colorectal cancer overexpresses markers of resistance to 5-FU and oxaliplatin, leading to shorter disease-free survival in patients treated with 5-FU.
Supporting Evidence
- Mucinous tumours significantly overexpressed TYMS and GSTP1 compared to nonmucinous tumours.
- Patients with mucinous tumours had a median disease-free survival of 13.8 months when treated with 5-FU.
- The expression of TYMS was significantly higher in mucinous tumours than in nonmucinous tumours.
Takeaway
Mucinous colorectal cancer is a type of cancer that doesn't respond as well to certain treatments, which means patients might not do as well as those with other types of colorectal cancer.
Methodology
The study reviewed 51 Dukes stage C colorectal cancer specimens, comparing gene expression in mucinous and nonmucinous tumours using TaqMan RT–PCR.
Potential Biases
The selection of tumours was not randomized, and treatment regimens were not standardized.
Limitations
The study had a limited follow-up period and was retrospective, which may affect the reliability of the findings.
Participant Demographics
The study included 21 patients with mucinous adenocarcinomas and 30 with nonmucinous adenocarcinomas, with no significant differences in age, gender, or tumour characteristics.
Statistical Information
P-Value
0.053
Confidence Interval
[95% CI 5.8, 30.0]
Statistical Significance
p=0.053
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website